Compare Coinbase Global, Inc. (COIN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Coinbase Global, Inc. trades at $149.03 (market cap $39.23B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Coinbase Global, Inc. is far larger — about 22× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| COIN | RXRX | |
|---|---|---|
Market Cap | $39.23B | $1.78B |
Sector | Technology | Health |
52-Week High | $387.27 | $6.79 |
52-Week Low | $141.09 | $2.84 |
Enterprise Value | $36.88B | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $153.6, up 5.63% in the past 24 hours, but technical indicators signal a bearish trend with resistance near $157. The company reported Q2 2026 revenue of $1.22 billion, missing estimates, and a net loss of $359.5 million, though adjusted EBITDA remained positive for the 14th consecutive quarter. Analyst consensus is a Buy with a $207.20 price target, but recent news highlights crypto market weakness and a Zacks Strong Sell rating on August 6, 2026.
The outlook is mixed: strong cash flow and market share growth offer upside, but consecutive earnings misses and high valuation ratios pose risks. Investors face volatility from crypto market dependence and competitive pressures, requiring caution despite Wall Street's bullish average target.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
